Skip to main content


Placeholder slot

This page contains brief information about olaratumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Olaratumab is approved to be used with doxorubicin to treat:

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that olaratumab provides a clinical benefit in these patients.

On January 24, 2019, FDA announced that the confirmatory trial of olaratumab did not confirm a clinical benefit. FDA advised that patients with soft tissue sarcoma who are receiving olaratumab talk with their doctors about whether to continue taking the drug and that no new patients should receive olaratumab outside of a clinical trial.

Olaratumab is also being studied in the treatment of other types of cancer.

More About Olaratumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Olaratumab - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Olaratumab Approved to Treat Advanced Soft Tissue Sarcoma

Targeted Cancer Therapies

Clinical Trials Accepting Patients

Find Clinical Trials for Olaratumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: